Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novo Nordisk Touts First-Line Potential For Oral Semaglutide

Jun 27 2018

• By Emily Hayes

Novo Nordisk Headquarters — Novo Nordisk headquarters

Related Content

Novo Nordisk Plans Value-based Contracts For GLP-1 Agonist Ozempic

Dec 07 2017

Novo Nordisk's Oral Semaglutide Succeeds In First Phase III, But Prompts Questions

Feb 23 2018

EASD 2016: Semaglutide Steals The Show With Impressive Cardiovascular Outcomes Data

Sep 16 2016

Novo's Semaglutide Outperforms Lilly's Trulicity In SUSTAIN 7

Aug 16 2017

Related Companies

Novo Nordisk A/S

Eli Lilly and Company

Merck & Co., Inc.

Additional Topics

Clinical Trials Research & Development Metabolic Disorders BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window